Compare BioNTech SE - ADR (BNTX) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Norwegian Cruise Line Holdings Ltd — how do they compare? BioNTech SE - ADR trades at $90.28 (market cap $22.86B), while Norwegian Cruise Line Holdings Ltd trades at $19.89 (market cap $8.93B). The key difference: BioNTech SE - ADR is far larger — about 2.6× Norwegian Cruise Line Holdings Ltd's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | NCLH | |
|---|---|---|
Market Cap | $22.86B | $8.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $26.94 |
52-Week Low | $83.89 | $14.79 |
Enterprise Value | $6.53B | $23.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Norwegian Cruise Line Holdings (NCLH) trades at $19.63, up 0.1% on the day, with a neutral technical signal and strong analyst consensus. Recent earnings beats and a 55.55% buy rating from analysts support optimism, though the stock faces headwinds from high debt levels and volatile cash flows. Revenue growth has improved from $4.8B in 2022 to $9.83B in 2025, but net margins remain modest at 4.3%.
The outlook is cautiously positive, with a consensus price target of $21.71 offering ~11% upside. Key opportunities include falling energy costs and robust booking trends, while risks involve elevated leverage and macroeconomic sensitivity. Investors should weigh solid fundamentals against balance sheet constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
